Method for the treatment of drug abuse

• US 20060252773A1
• Filed: 05/02/2006
• Published: 11/09/2006
• Est. Priority Date: 05/06/2005
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Ceci, Angelo
• Application Number:
  US11/381,130
• Publication Number:
  US 20060252773A1
• Time in Patent Office: Days
• US Class Current: 514/254.60
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 25/34 Tobacco-abuse
• CPC Class Codes: A61P 25/36 Opioid-abuse

Abstract

The invention relates to a method for the treatment of drug addiction, especially nicotine, ethanol and psychostimulants addiction, and for changing dependency-related behaviors of a person suffering from substance addiction in the course of such treatment, comprising the administration of a therpeutically effective amount of flibanserin.

Claims

1. ) A method for the treatment of drug addiction comprising the administration of a therapeutically effective amount of flibanserin, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or a solvate thereof, or a combination thereof, to a mammal suffering from drug addiction.

5. ) The method according to claim 1 characterized in that the drug is selected from nicotine, ethanol or a psychostimulant.

6. ) The method according to claim 1, characterized in that flibanserin is applied in form of a pharmaceutically acceptable acid addition salt selected from the salts formed by the acids selected from, succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

7. ) The method according to claim 6, characterized in that flibanserin is applied in form of flibanserin polymorph A.

8. ) The method accoridng to claim 7, characterized in that flibanserin is applied in a dosage range between about 0.1 to about 400 mg per day.

2. ) A method of ameliorating or eliminating effects of addiction to a drug of abuse in a mammal suffering from drug addiction, comprising the administration of a therapeutically effective amount of flibanserin, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or a solvate thereof, or a combination thereof, wherein said administration is in an amount sufficient to reduce drug dependency characteristics.

3. ) A method for changing addiction-related behavior of a mammal suffering from drug addiction comprising the administration of a therapeutically effective amount of flibanserin, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or a solvate thereof, or a combination thereof, wherein said administration is in an amount sufficient to diminish, inhibit or eliminate behavior associated with craving or use of said drug of abuse.

4. ) A method for alleviating or eliminating withdrawal symptoms in a mammal suffering from drug addiction, comprising the administration of a therapeutically effective amount of flibanserin, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or a solvate thereof, or a combination thereof, wherein said administration is in an amount sufficient to reduce withdrawal symptoms.